Table 1

Occurrence of PE compared with other cardiovascular events in patients admitted to hospital with sarcoidosis, compared with a reference cohort

OutcomeObservedExpectedRRLower CIUpper CIp Value
All ages
AAA2.002.700.750.092.720.69
CHD44.0043.801.000.731.350.98
Heart Failure21.0011.801.781.102.720.01
MI33.0028.601.150.791.620.41
PE14.007.301.921.053.230.01
DVT5.005.001.000.322.341.00
Strokes excluding SAH21.0018.301.150.711.760.53
SAH2.002.200.910.113.310.90
Under 65 years
AAA2.002.600.780.092.820.72
CHD36.0037.800.950.671.320.77
Heart Failure18.008.202.221.313.510.00
MI25.0023.901.040.681.540.83
PE13.006.601.981.053.390.01
DVT5.004.101.230.402.880.65
Strokes excluding SAH17.0012.601.350.792.170.22
SAH2.002.001.020.123.720.98
All ages excluding DVT and PE diagnosed within first year of admission
AAA2.002.600.770.092.780.95
CHD42.0041.901.000.721.360.99
Heart Failure20.0011.301.781.092.750.01
MI32.0027.201.180.811.670.35
PE12.006.501.870.963.270.03
DVT4.004.500.890.242.290.82
Strokes excluding SAH20.0017.001.180.721.820.47
SAH1.002.000.500.012.800.48
  • Patients in the reference cohort were drawn from a group who were admitted to hospital with squint, otitis media, haemorrhoids, deflected septum, nasal polyps, impacted tooth, ingrowing toenail, bunions, sebaceous cyst, superficial injury and appendicectomy.

  • AAA, abdominal aortic aneurysm, CHD, coronary heart disease; DVT, deep vein thrombosis, PE, pulmonary embolism; RR, rate ratio; SAH, subarachnoid haemorrhage.